Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2686 to 2700 of 9035 results

  1. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 8 June 2026.

  2. Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646]

    In development Reference number: GID-TA11858 Expected publication date: TBC

  3. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    In development Reference number: GID-TA11558 Expected publication date: TBC

  4. Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]

    In development Reference number: GID-TA11509 Expected publication date:  24 February 2027

  5. Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    In development Reference number: GID-TA11643 Expected publication date:  17 September 2026

  6. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date:  17 September 2026

  7. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development Reference number: GID-TA10575 Expected publication date:  05 August 2026

  8. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  9. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

  10. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  11. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

  12. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  13. Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)

    Summary of the evidence on delafloxacin for community-acquired pneumonia in adults

  14. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  15. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making